Administration of OKT3 as a two-hour infusion attenuates first-dose side effects

Transplantation

Volumn 64, Issue 11, 1997, Pages 1620-1623

  Buysmann, Saskia ^a   Hack, C Erik ^a   Van Diepen, Frank N J ^a   Surachno, Janto ^a   Ten Berge, Ineke J M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY CD3; OKT 3; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN TISSUE; INFLAMMATION; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ANAPHYLATOXINS; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3A; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; INFUSIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MICE; MUROMONAB-CD3; NEUTROPHIL ACTIVATION;

EID: 0031444192     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199712150-00024     Document Type: Article

References (12)

1. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
2. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
3. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697.
4. Raasveld MHM, Bemelman FJ, Schellekens PThA, et al. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int 1993; 43: 1140.
5. Büsing M, Mellert J, Greger B, Hopt UT. Acute pulmonary insufficiency due to OKT3 therapy. Transplant Proc 1990; 22: 1779.
6. Chang TW, Kung PC, Gingras SP, Goldstein G. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? Proc Natl Acad Sci USA 1981; 78: 1805.
7. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305: 308.
8. Parlevliet KJ, ten Berge RJM, Raasveld MHM, Surachno J, Wilmink JM, Schellekens PThA. Low-dose OKT3 induction therapy following renal transplantation: a controlled study. Nephrol Dial Transplant 1994; 9: 698.
9. Bemelman FJ, Parlevliet KJ, Schellekens PThA, Surachno S, van Royen EA, ten Berge RJM. Sequestration of labelled granulocytes in the lungs following administration of OKT3 is dose-dependent. Transplant Immunol 1994; 2: 47.
10. Bemelman FJ, Buysmann S, Surachno S, Wilmink JM, Schellekens PThA, ten Berge RJM. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. Kidney Int 1994; 46: 1674.
11. Chatenoud L, Legendre C, Ferran C, Bach JF, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome: dosage and kinetics prerequisites. Transplantation 1991; 51: 334.
12. Charpentier B, Hiesse C, Lantz O, et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992; 54: 997.